Repurposed Drug Protocol for dogs
Also searched as: fenbendazole ivermectin protocol, Panacur cancer protocol
The short answer
Fenbendazole with ivermectin, sometimes with thymosin alpha-1 — two approved antiparasitics used off-label at extended schedules.
What it is and why these compounds
This protocol combines two drugs that are FDA-approved for dogs as antiparasitics and being investigated off-label for anticancer activity. Their proposed mechanisms differ — fenbendazole destabilises microtubules, ivermectin is reported to modulate Wnt and Akt/mTOR signalling — which is the argument for using them together. Both have long safety records at their labelled doses, and this is exactly what makes the protocol easy to underestimate: the oncology schedules involve months of dosing rather than a three-day deworming course, which is a materially different exposure. Bone marrow suppression with extended fenbendazole and MDR1-related neurotoxicity with ivermectin are both documented.
Compounds in this protocol
A common FDA-approved dewormer under investigation for anticancer activity.
A Nobel Prize-winning antiparasitic with published in vitro canine mammary tumour data.
Approved in more than 35 countries for human use as Zadaxin — the strongest evidence base on this site.
Before starting
These are the decisions that determine whether this protocol is appropriate at all.
⚠ Read first
Fenbendazole must not be combined with vincristine or paclitaxel — overlapping microtubule mechanisms create additive toxicity risk. Any dog on conventional chemotherapy needs its oncologist involved first.
Caution
MDR1 testing before ivermectin is mandatory and the consequence of skipping it can be fatal.
Caution
Pancytopenia has been documented in dogs on extended daily fenbendazole. Monthly CBC is the safeguard, not an optional extra.
Caution
The safety record of these drugs at labelled doses does not transfer to months of continuous use.
Example timeline
A representative schedule drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Week 1Testing and conservative start
What owners observe
MDR1 testing must be complete before the first ivermectin dose. Give both drugs with a fatty meal — each is highly lipophilic and absorption depends on it. Watch for neurological signs.
Clinical monitoring
Baseline CBC, liver panel, chemistry. Fenbendazole 50 mg/kg/day for three consecutive days then four off. Ivermectin from 0.3 mg/kg/day.
- 2Weeks 2–4Monitoring
What owners observe
Watch specifically for pale gums, lethargy, or appetite loss — these can indicate bone marrow suppression and warrant immediate attention rather than waiting for the next scheduled check.
Clinical monitoring
Repeat CBC at weeks 2 and 4 to monitor for pancytopenia. Liver values should remain stable. Ivermectin may titrate toward 0.6 mg/kg if tolerated.
- 3Weeks 4–12+Continue if tolerated
What owners observe
The four-day fenbendazole break each week is not padding — it is the part of the schedule that allows liver and marrow recovery. Quality of life is the endpoint.
Clinical monitoring
Monthly CBC and liver panel. Do not exceed 0.6 mg/kg/day ivermectin. Thymosin alpha-1 may be added for immune support.
Investigated for
Common questions
What is the Repurposed Drug Protocol for dogs?+
Fenbendazole with ivermectin, sometimes with thymosin alpha-1 — two approved antiparasitics used off-label at extended schedules. It combines Fenbendazole, Ivermectin, Thymosin Alpha-1.
Is the Repurposed Drug Protocol safe for dogs?+
Fenbendazole must not be combined with vincristine or paclitaxel — overlapping microtubule mechanisms create additive toxicity risk. Any dog on conventional chemotherapy needs its oncologist involved first. MDR1 testing before ivermectin is mandatory and the consequence of skipping it can be fatal. Pancytopenia has been documented in dogs on extended daily fenbendazole. Monthly CBC is the safeguard, not an optional extra. The safety record of these drugs at labelled doses does not transfer to months of continuous use.
How long does the Repurposed Drug Protocol run?+
The example timeline runs from week 1 through weeks 4–12+. Actual duration should be set by the veterinarian managing the case and adjusted on response.
References
- 1.Dogra N, Kumar A, Mukhopadhyay T Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018. PMID 30093705
- 2.Song B, et al. Fenbendazole: An Anticancer Agent? A Case Series of Self-Administration. Case Reports in Oncology, 2025. PMC12215191
- 3.CANINE STUDYNguyen J, et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 2024. View source
- 4.Leach B, et al. Fenbendazole as a Potential Anticancer Drug. Anticancer Research, 2012. PMC3580766
- 5.Kim YJ, et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology, 2023. PMC10670425
- 6.CANINE STUDYZhu M, et al. Ivermectin-induced apoptosis of canine mammary tumor cells through regulation of the cell cycle and WNT signaling. BMC Veterinary Research, 2019. PMC6679554
- 7.Juarez M, Schcolnik-Cabrera A, Duenas-Gonzalez A The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018. PMID 29344093
- 8.Tang M, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 2021. PMC7505114
- 9.Dominguez-Gomez G, et al. Ivermectin as an inhibitor of cancer stem-like cells: antitumor effects at clinically feasible concentrations. Cancer Chemotherapy and Pharmacology, 2020. View source
- 10.King R, Tuthill C Immune modulation with thymosin alpha 1 treatment. Vitamins and Hormones, 2016. PMID 27450734
- 11.Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
- 12.Bellet MM, et al. Thymosin Alpha 1 in Cancer Therapy: Where Do We Stand?. Frontiers in Oncology, 2019. View source
- 13.Guo Y, et al. Thymosin alpha 1 suppresses proliferation of breast cancer cells via PTEN/PI3K/Akt/mTOR. Apoptosis, 2015. View source
- 14.Wang F, et al. Thymosin alpha-1-Fc modulates the immune system with prolonged half-life. Scientific Reports, 2018. PMID 30120313
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.